Literature DB >> 33779553

Desensitization to Methimazole.

Alaleh Mazhari1, Mary Ann Emanuele2, Baltazar Espiritu2.   

Abstract

OBJECTIVE: Thionamides (methimazole and propylthiouracil) have been associated with common side effects, such as rash and pruritus, and rare but serious adverse effects, such as agranulocytosis and hepatotoxicity. Methimazole is usually the preferred thionamide for the treatment of hyperthyroidism if the patient is not planning to conceive or not in the first trimester of pregnancy, given the less frequent dosing and lower risk of hepatotoxicity. In patients who experience rash or itching when treated with methimazole, switching them to propylthiouracil is one treatment option. Here we report our experience regarding desensitization to methimazole to allow continued treatment with methimazole as an alternative management option.
METHODS: We conducted a retrospective chart review of patients at a single institution who had side effects to methimazole and who were desensitized to methimazole under the supervision of an allergist. A total of 7 patients were included who experienced side effects to methimazole that did not include agranulocytosis or hepatotoxicity.
RESULTS: All 7 patients were able to take methimazole for treatment of their hyperthyroidism, either for continued medical therapy or as a bridge to definitive therapy, with either surgery or radioactive iodine treatment.
CONCLUSION: Under the supervision of an allergist, desensitization to methimazole is an option for treating patients who experience side effects to methimazole (excluding agranulocytosis and hepatotoxicity).
Copyright © 2020 AACE. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MMI; PTU; allergic reaction; desensitization; methimazole; propylthiouracil

Mesh:

Substances:

Year:  2020        PMID: 33779553     DOI: 10.1016/j.eprac.2020.10.019

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  1 in total

1.  The Potential Prebiotic Berberine Combined With Methimazole Improved the Therapeutic Effect of Graves' Disease Patients Through Regulating the Intestinal Microbiome.

Authors:  Zhe Han; Chaoping Cen; Qianying Ou; Yonggui Pan; Jiachao Zhang; Dongxue Huo; Kaining Chen
Journal:  Front Immunol       Date:  2022-01-10       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.